Shuttle Pharmaceuticals Holdings, Inc. reported a net loss of approximately $11.7 million for the fiscal year ending December 31, 2025, compared to a net loss of $9.1 million in the previous year, marking an increase of 28%. The company did not generate any revenue during this period. Total operating expenses rose to $11.9 million, a 55% increase from $7.7 million in 2024, driven primarily by a significant rise in general and administrative expenses, which surged by 307% to $5.7 million, largely due to investor relations advertising costs. Research and development expenses also increased by 12% to $4.1 million, reflecting costs associated with the wind-down of clinical trials for Ropidoxuridine, the company's lead product candidate.
In a strategic move, Shuttle Pharmaceuticals acquired the assets of Molecule.ai, a pharmaceutical software company specializing in AI-driven platforms for molecular discovery, for a total consideration of approximately $10.1 million. This acquisition, finalized on November 21, 2025, included a cash payment of $3 million and contingent payments based on technology development milestones. Concurrently, the company announced plans to discontinue its clinical trials for Ropidoxuridine, indicating a shift in focus towards leveraging the capabilities of the Molecule.ai platform to enhance its drug discovery and development efforts.
Operationally, Shuttle Pharmaceuticals faced challenges, reporting a working capital deficit of approximately $7.5 million as of December 31, 2025, compared to a working capital surplus of $0.7 million the previous year. The company’s total current assets decreased significantly to $0.5 million from $2.2 million, primarily due to cash outflows related to the Molecule.ai acquisition and costs associated with winding down clinical trials. Current liabilities increased sharply to $8 million, reflecting the financial obligations tied to the acquisition and other operational costs.
The company has been actively working to regain compliance with Nasdaq listing requirements, having faced deficiencies in both stockholders' equity and minimum bid price. Following a series of equity financings, including a public offering in March 2026 that raised approximately $3.5 million, Shuttle Pharmaceuticals believes it has regained compliance with Nasdaq's stockholders' equity requirement. However, the company continues to express uncertainty regarding its ability to sustain operations without additional financing, emphasizing the need for ongoing capital to support its business model and strategic initiatives.
Looking ahead, Shuttle Pharmaceuticals aims to capitalize on the capabilities of the Molecule.ai platform to drive future growth and revenue generation. The company is focused on enhancing its product offerings and expanding its market presence, although it acknowledges the inherent risks and uncertainties associated with its business model and the competitive landscape in the pharmaceutical and biotechnology sectors.
About Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals develops novel cancer therapies focused on enhancing radiation therapy. Its pipeline includes radiation sensitizers, HDAC inhibitors, and diagnostic biomarkers aimed at solid tumors like glioblastoma and prostate cancer. The company leverages proprietary platform technologies, collaborates with academic institutions, and seeks regulatory approvals to deliver safer, more effective cancer treatments with potential for personalized medicine applications.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.